EPS Q/Q společnosti Aerie Pharmaceuticals Inc
Jaká je hodnota metriky EPS Q/Q společnosti Aerie Pharmaceuticals Inc?
Hodnota metriky EPS Q/Q společnosti Aerie Pharmaceuticals Inc je -52.24%
Jaká je definice metriky EPS Q/Q?
Čtvrtletní růst EPS (Quarterly EPS growth rate) ze čtvrtletí na čtvrtletí, je nárůst EPS společnosti za poslední čtyři čtvrtletí v porovnání s výsledky z minulých čtyř čtvrtletí.
The earnings per share growth rate is an important factor for judging a company's value. EPS growth rate gives a good picture of the rate at which the company has grown its profitability in respect to the total number of shares. Comparing EPS history with stock price history helps determine the most likely future direction of the stock price.
Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.
EPS Q/Q společností v sektoru Health Care sektor na NASDAQ ve srovnání se společností Aerie Pharmaceuticals Inc
Čemu se věnuje společnost Aerie Pharmaceuticals Inc?
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.
Firmy s metrikou eps q/q podobnou společnosti Aerie Pharmaceuticals Inc
- Hodnota metriky EPS Q/Q společnosti Kiniksa Pharmaceuticals International Plc je -52.46%
- Hodnota metriky EPS Q/Q společnosti Root je -52.41%
- Hodnota metriky EPS Q/Q společnosti THL Credit je -52.38%
- Hodnota metriky EPS Q/Q společnosti EuroDry je -52.38%
- Hodnota metriky EPS Q/Q společnosti Superior Industries International je -52.38%
- Hodnota metriky EPS Q/Q společnosti Cellectis je -52.27%
- Hodnota metriky EPS Q/Q společnosti Aerie Pharmaceuticals Inc je -52.24%
- Hodnota metriky EPS Q/Q společnosti Sap SE je -52.20%
- Hodnota metriky EPS Q/Q společnosti Catalent je -52.11%
- Hodnota metriky EPS Q/Q společnosti Moelis & Co je -52.10%
- Hodnota metriky EPS Q/Q společnosti Flagstar je -52.04%
- Hodnota metriky EPS Q/Q společnosti Sabre Corp je -51.92%
- Hodnota metriky EPS Q/Q společnosti Ocuphire Pharma je -51.92%